CareDx, Inc. (CDNA) - Q1 2026 10-Q Summary
Business Context and Reporting Period
CareDx, Inc. is a precision medicine company focused on improving outcomes for transplant patients through non-invasive molecular testing, laboratory products, and digital health solutions. This report covers the quarterly period ended March 31, 2026. The company operates primarily in the United States with additional facilities in Sweden and Australia.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $117.7 million | $84.7 million |
| Net Income (Loss) | $2.8 million | ($10.4 million) |
| Operating Income (Loss) | $1.2 million | ($13.4 million) |
| Cash from Operating Activities | $4.3 million | ($26.6 million) |
| Cash, Cash Equivalents & Marketable Securities | $198.1 million | N/A |
| Accumulated Deficit | ($732.6 million) | N/A |
| Shares Outstanding | 51.3 million | 55.5 million (weighted avg) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 39% year-over-year, driven primarily by a 48% increase in testing services revenue ($91.4 million) and a 33% increase in patient and digital solutions revenue ($16.0 million). Product revenue declined 4% to $10.3 million.
- Profitability Turnaround: The company reported a net income of $2.8 million compared to a net loss of $10.4 million in Q1 2025. This shift was largely due to a significant reduction in litigation settlement expenses (down 89% to $0.6 million from $5.4 million) and strong revenue growth.
- Operating Expenses: Total operating expenses increased 19% to $116.5 million. Increases were noted in Sales and Marketing (+32%) and General and Administrative (+34%) expenses, attributed to personnel costs and stock-based compensation.
- Cash Flow: Operating cash flow turned positive at $4.3 million, a significant improvement from the $26.6 million outflow in the prior year period.
Guidance, Outlook, and Risks
Subsequent Events & Strategic Moves:
- Divestiture: On April 15, 2026, CareDx agreed to sell its lab products business (CareDx AB) to EuroBio Scientific for $170 million in cash.
- Acquisition: On April 28, 2026, CareDx agreed to acquire Naveris, Inc. for $160 million in cash, plus up to $100 million in contingent milestone payments.
- Share Repurchase: On April 24, 2026, the Board authorized a new $100 million share repurchase program.
Risks and Contingencies:
- Reimbursement: Approximately 27% of revenue is derived from Medicare. The company faces potential reimbursement rate adjustments under the PAMA law and ongoing Local Coverage Determination (LCD) reviews which could impact pricing.
- Litigation: While a $96.3 million liability related to Natera patent infringement was derecognized following a court ruling invalidating the patent, Natera has appealed. The company also settled a securities class action for $20.25 million in late 2025 and reached an agreement in principle for derivative actions totaling $0.6 million in attorney fees.
- Regulatory: The company is subject to FDA oversight of Laboratory Developed Tests (LDTs) and CLIA regulations. Changes in these regulations could require costly clinical trials or premarket approvals.
Investor Verification Checklist
- Verify the closing status and regulatory approvals for the $170 million divestiture of the lab products business and the $160 million acquisition of Naveris.
- Monitor the status of the Natera patent appeal and any potential reinstatement of the $96.3 million liability.
- Track Medicare reimbursement rate changes effective January 1, 2026, and the outcome of the proposed LCD revisions regarding bundled payments.
- Assess the impact of the new $100 million share repurchase program on future liquidity and capital allocation.
- Review the integration plan for Naveris and the transition of the divested lab products business to ensure no disruption to core testing services.